The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …